ESMO Immuno-Oncology Congress 2017

Oncology Meeting Resources

07 Dec - 10 Dec 2017, Geneva, Switzerland

ESMO Immuno Oncology Congress 2017

ESMO Immuno Oncology Congress 2017 reflects ESMO’s commitment to providing oncologists who need to learn how to apply the latest research and standards of care in the immunotherapy of cancer with a comprehensive update in an environment rich with highly specialised professionals.

Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access.
Congress attendees should access via the ESMO Conferences platform.
Resources will be added as they become available.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme |Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...017/PET-imaging-of-monocytes-and-macrophages

Date: 07 Dec 2017
Presenter: Tony Lahoutte
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...ET-imaging-with-immune-checkpoint-inhibitors

Date: 07 Dec 2017
Presenter: E.G. Elisabeth de Vries

https://oncologypro.esmo.org/Meeting-Resour...ession-as-a-predictive-and-prognostic-factor

Date: 07 Dec 2017
Presenter: Keith Kerr
Resources: Presentation, Webcast
Topics: Oesophageal Cancer, Gastrointestinal Cancers, Translational Research

https://oncologypro.esmo.org/Meeting-Resour...unohistochemistry-Assays-LDTs-and-validation

Date: 07 Dec 2017
Presenter: Keith Miller

https://oncologypro.esmo.org/Meeting-Resour...cts-of-VEGF-targeted-therapy-Fact-or-fiction

Date: 07 Dec 2017
Presenter: Thomas Powles
Resources: Presentation, Webcast
Topics: Gastric Cancer, Gastrointestinal Cancers, Lung and other Thoracic Tumours, Translational Research

https://oncologypro.esmo.org/Meeting-Resour...ogy-Congress-2017/Invited-Discussant-LBA1_PR

Date: 07 Dec 2017
Presenter: Naiyer Rizvi
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...-1L-non-squamous-metastatic-NSCLC-IMpower150

BackgroundAtezolizumab (atezo; anti–PD-L1) inhibits PD-L1 binding to PD-1 and B7.1, restoring anti-cancer immunity. Bev may further enhance atezo efficacy by inhibiting VEGF immunosuppression and promoting T-cell tumour infiltration.

Date: 07 Dec 2017
Presenter: Martin Reck
Resources: Abstract, Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...-with-Unresectable-or-Metastatic-Melanoma-5O

BackgroundOmaveloxolone (Omav) reduces production of reactive oxygen and nitrogen species by myeloid derived suppressor cells (MDSCs) and restores immune surveillance in preclinical cancer models.

Date: 08 Dec 2017
Presenter: Sapna Patel
Resources: Abstract, Presentation, Webcast
Topics: Lymphomas, Haematologic Malignancies, Translational Research

https://oncologypro.esmo.org/Meeting-Resour...ion-of-T-cells-in-the-peritumoural-stroma-8O

BackgroundIdentifying determinants of response to cancer immunotherapy is critical for extending therapeutic benefit to more patients. Atezolizumab (anti–PD-L1) was approved in the US for the treatment...

Date: 08 Dec 2017
Presenter: Sanjeev Mariathasan
Resources: Abstract
Topics: Colon Cancer, Rectal Cancer, Gastrointestinal Cancers

https://oncologypro.esmo.org/Meeting-Resour...d-cells-in-the-tumor-microenvironment-TME-4O

BackgroundE7046 is a selective small molecule antagonist of the prostaglandin E2 receptor-type-4 that inhibits the differentiation of monocytic myeloid lineage cells towards a pro-tumorigenic phenotype in the TME.

Date: 08 Dec 2017
Presenter: Aparna Parikh
Resources: Abstract, Presentation, Webcast
Topics: Colon Cancer, Rectal Cancer, Gastrointestinal Cancers, Translational Research